

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A method for ~~administering a composition with antiangiogenic activity~~ inhibiting VEGF-induced cell proliferation in a subject in need thereof, comprising, administering to ~~[[a]] said subject in need thereof~~ an effective amount of ~~o-ATP~~ oxidized adenosine triphosphate (o-ATP).

2. (currently amended) The method according to claim 1, ~~for the treatment of diseases which in their onset or progression involve angiogenesis~~ wherein the subject has and is treated for a disease involving VEGF-induced cell proliferation.

3. (currently amended) The method according to claim 1, ~~for the treatment of ocular diseases, atherosclerotic processes or tumours~~ wherein the subject has and is treated for cancer.

4. (currently amended) The method according to claim 3, ~~for the treatment of carcinomas, lymphomas, leukemias, sarcomas, melanomas, gliomas, neuroblastomas~~ wherein the cancer is selected from the group consisting of lymphoma and leukemia.

5. (currently amended) ~~Therapeutic~~ A preparation ~~containing o-ATP~~ comprising oxidized adenosine triphosphate (o-ATP) in combination with ~~an antitumor~~ a substance selected from the group consisting of cytotoxic [[or]] compounds, cytostatic

compounds, antimetabolites, alkaloids, antibiotics, alkylating agents, peptides, biological response modulators and cytokines, ~~for simultaneous, separate or sequential use in tumour treatment.~~

6. (currently amended) ~~Therapeutic~~ A preparation ~~containing o-ATP comprising oxidized adenosine triphosphate (o-ATP)~~ in combination with ~~an antiatherosclerotic~~ a substance selected from the group consisting of lipid lowering drugs and statins, ~~for simultaneous, separate or sequential use in the treatment of atherosclerotic processes.~~

7. (new) The preparation according to claim 5, wherein the preparation is in a form selected from the group consisting of tablet, pill, capsule, granulate, powder, suppository, solution, spray, syrup, cream, ointment, gel, paste, lotion, emulsion and suspension.

8. (new) The preparation according to claim 6, wherein the preparation is in a form selected from the group consisting of tablet, pill, capsule, granulate, powder, suppository, solution, spray, syrup, cream, ointment, gel, paste, lotion, emulsion and suspension.

9. (new) A method for inhibiting VEGF-induced cell proliferation of endothelial cells, comprising: administering to said endothelial cells an effective amount of oxidized adenosine triphosphate (o-ATP).

10. (new) The method according to claim 9, wherein the endothelial cells are human endothelial cells.

11. (new) The method according to claim 10, wherein the endothelial cells are human umbilical vein endothelial cells.

12. (new) The method according to claim 9, wherein the cells are human endothelial cells of a subject.

13. (new) The method according to claim 12, wherein the o-ATP is administered to said subject in a daily dosage of 0.01 to 100 mg per kg of body weight of said patient.

14. (new) The method according to claim 12, wherein the o-ATP is administered in the form of a preparation selected from the group consisting of tablet, pill, capsule, granulate, powder, suppository, solution, spray, syrup, cream, ointment, gel, paste, lotion, emulsion and suspension.

15. (new) The method according to claim 15, wherein the o-ATP is administered in a daily dosage of 0.01 to 100 mg per kg of body weight of said patient.